Значок книги

Adverse events following immunization of co- and separate administration of DTaP-IPV/Hib vaccines: A real-world comparative study

To fully understand the safety of DTaP-IPV/Hib vaccination, we evaluated the differences between DTaP-IPV/Hib co-administration and separate administration of the DTaP, IPV and Hib vaccines (DTaP+IPV+Hib) based on adverse events following immunization (AEFI). All AEFI reported in Hebei Province, Chi...

Полное описание

Сохранить в:

Библиографические подробности
Главные авторы:	Yiqing Zhu (Автор), Li Sun (Автор), Yihan Wang (Автор), Jinghui Wang (Автор), Yafei Wang (Автор), Jing Li (Автор), Lina Wang (Автор), Yu Guo (Автор)
Формат:	‌
Опубликовано:	Taylor & Francis Group, 2024-12-01T00:00:00Z.
Предметы:	article
Online-ссылка:	Connect to this object online.
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы

A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)
по: Andrea Guerra, и др.
Опубликовано: (2024)

The Implementation of Pentavalent Vaccine DTaP/IPV/Hib within National Immunization Schedule
по: Irina V. Mikheeva, и др.
Опубликовано: (2019)

DTaP5-IPV-Hib-HepB, a hexavalent vaccine for infants and toddlers
по: Andrew W. Lee, и др.
Опубликовано: (2017)

DTaP-IPV-HB-Hib vaccine (Hexaxim): an update 10 years after first licensure
по: Florence Boisnard, и др.
Опубликовано: (2023)

Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China
по: Aodi Huang, и др.
Опубликовано: (2024)

Safety and immunogenicity of a fully-liquid DTaP-IPV-Hib-HepB vaccine (Vaxelis™) in premature infants
по: Marissa B. Wilck, и др.
Опубликовано: (2021)

Rejoinder to comments on ''Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China''
по: Floriano Amimo
Опубликовано: (2024)

A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients
по: Andrew Dakin, и др.
Опубликовано: (2023)

Immunogenicity and safety of DTaP/Hib combined vaccination at different inoculation sites among infants
по: Zhen-jiang LIU, и др.
Опубликовано: (2022)

Demonstration of durable hepatitis B immune memory in children vaccinated with a DTaP5-IPV-HepB-Hib infant-toddler series 7 to 8 years previously
по: Anitta Ahonen, и др.
Опубликовано: (2022)

Surveillance for adverse events following immunization with DTaP-containing combination vaccines in Linping, China, 2019-2022
по: Qinghua Chen, и др.
Опубликовано: (2024)

Immunogenicity and safety of a DTaP-IPV//PRP~T combination vaccine given with hepatitis B vaccine: a randomized open-label trial
по: Maria Rosario Capeding, и др.
Опубликовано: (2008)

Concomitant administration of diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine derived from Sabin strains (DTaP-sIPV) with pentavalent rotavirus vaccine in Japanese infants
по: Yoshiyuki Tanaka, и др.
Опубликовано: (2017)

A prospective, observational, multi-center, post-marketing safety surveillance study of the GSK combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b invasive infections (DTaP-IPV/Hib) in South Korean infants
по: Diego Mpia Elenge, и др.
Опубликовано: (2024)

Proactive surveillance on DTaP vaccination-induced adverse local reac-tions among infants in a county of Jiangsu province
по: Peng ZHANG, и др.
Опубликовано: (2024)

Post-marketing surveillance to assess the safety and tolerability of a combined diphtheria, tetanus, acellular pertussis and inactivated poliovirus vaccine (DTaP-IPV) in Korean children
по: Soon Min Lee, и др.
Опубликовано: (2019)

Improving childhood vaccination coverage rates: the case of fourth dose of DTaP
по: Sarah J. Clark, и др.
Опубликовано: (2020)

Persistence of hepatitis B immune memory until 9-10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP∼T vaccination at 2, 4 and 6 months
по: Pope Kosalaraksa, и др.
Опубликовано: (2018)

Safety and immunogenicity of a combined DTacP-sIPV-Hib vaccine in animal models
по: Yuntao Zhang, и др.
Опубликовано: (2022)

A DTAP-IPV//PRP~T VACCINE: A REVIEW OF 16 YEARS' CLINICAL EXPERIENCE
по: Stanley A. Plotkin, и др.
Опубликовано: (2012)

Innovation of Shallot (Allium Ascalonicum L) Essential Oil for Fever Reduction in Infants Post DTaP Immunization
по: Setiawandari Setiawandari, и др.
Опубликовано: (2021)

Surveillance for adverse events following immunization in Hebei Province, China, 2018-2020
по: Li Sun, и др.
Опубликовано: (2024)

Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries
по: Marina George, и др.
Опубликовано: (2023)

A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration
по: The MMR-158 Study Group
Опубликовано: (2019)

Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib in Indian infants
по: Sanjay K. Lalwani, и др.
Опубликовано: (2017)

Guillain Barré syndrome after combined diphtheria, tetanus, and acellular pertussis (DTaP) vaccine: A rare pediatric case report and review of literature
по: Meichen Pan, и др.
Опубликовано: (2023)

Surveillance of adverse events following the introduction of inactivated poliovirus vaccine made from Sabin strains (sIPV) to the Chinese EPI and a comparison with adverse events following inactivated poliovirus vaccine made from wild strains (wIPV) in Jiangsu, China
по: Guodong Kang, и др.
Опубликовано: (2021)

Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine
по: Julianne Bayliss, и др.
Опубликовано: (2021)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
по: Yankun Liang, и др.
Опубликовано: (2023)

A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases
по: Menglin He, и др.
Опубликовано: (2024)

Surveillance analysis of adverse events following immunization with the bivalent human papillomavirus vaccine and recombinant human papillomavirus 9-valent vaccine in Hebei province from 2018 to 2022
по: Jinghui WANG, и др.
Опубликовано: (2024)

Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants
по: Yanping Li, и др.
Опубликовано: (2017)

A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system
по: Kaixuan Wang, и др.
Опубликовано: (2024)

A real-world pharmacovigilance study of FDA adverse event reporting system events for diazepam
по: Weizhen He, и др.
Опубликовано: (2024)

Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database
по: Jing Peng, и др.
Опубликовано: (2022)

Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration's adverse event reporting system databases
по: Qiaofang Liang, и др.
Опубликовано: (2024)

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system
по: Huqun Li, и др.
Опубликовано: (2023)

The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database
по: Xiaogan Wang, и др.
Опубликовано: (2024)

Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system
по: Huqun Li, и др.
Опубликовано: (2024)

Anaphylaxis Associated With Allergen Specific Immunotherapy, Omalizumab, and Dupilumab: A Real World Study Based on the US Food and Drug Administration Adverse Event Reporting System
по: Sainan Bian, и др.
Опубликовано: (2021)